Alexandria Hammond
Stock Analyst at B of A Securities
(2.78)
# 1,721
Out of 5,143 analysts
15
Total ratings
77.78%
Success rate
14.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $440.00 | +20.23% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $228.44 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $123.93 | +8.93% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $772.19 | +48.93% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $27.14 | -7.89% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $50.52 | -20.82% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $1,042.15 | -4.04% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $246.28 | -22.85% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $147.64 | -25.49% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $61.60 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $195.13 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $440.00
Upside: +20.23%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $228.44
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $123.93
Upside: +8.93%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $772.19
Upside: +48.93%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $27.14
Upside: -7.89%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $50.52
Upside: -20.82%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $1,042.15
Upside: -4.04%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $246.28
Upside: -22.85%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $147.64
Upside: -25.49%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $61.60
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $195.13
Upside: -